	US 11,850,252 B2
	Use of nor-ursodeoxycholic acid for reducing liver fat
Markus Pröls, Freiburg/Breisgau (DE); Roland Greinwald, Kenzingen (DE); Michael Trauner, Vienna (AT); and Peter Fickert, Graz (AT)
Assigned to DR. FALK PHARMA GMBH, Freiburg (DE)
Appl. No. 16/652,044
Filed by Dr. Falk Pharma GmbH, Freiburg (DE)
PCT Filed Sep. 28, 2018, PCT No. PCT/EP2018/076461 § 371(c)(1), (2) Date Mar. 28, 2020, PCT Pub. No. WO2019/063790, PCT Pub. Date Apr. 4, 2019.
Claims priority of application No. 17193777 (EP), filed on Sep. 28, 2017.
Prior Publication US 2020/0246357 A1, Aug. 6, 2020
Int. Cl. A61K 31/575 (2006.01); A61P 1/16 (2006.01); A61K 45/06 (2006.01)

CPC A61K 31/575 (2013.01) [A61P 1/16 (2018.01); A61K 45/06 (2013.01)]

16 Claims

1. A method of treating hepatic steatosis with Nor-UDCA, wherein said treating comprises administering to a human patient in need thereof which has not yet progressed to steatohepatitis an effective amount of Nor-UDCA, and wherein said human patient has a hepatic fat fraction of greater than 20%, wherein the Nor-UDCA is administered to the patient once per day, wherein the dose of Nor-UDCA administered to the human patient is from 1,000 mg/day to 2,500 mg/day, wherein said treating reduces the hepatic fat fraction of the patient by at least 2 percentage points, and wherein said human patient does not show signs of inflammation or hepatitis.